GlassScriptPhysician profile
John P Dies
NPI 1477971083
$1,931.65
in general payments reported to CMS, 2019-2025
18 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $347 · 2023: $514 · 2024: $534 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.40 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $803.27 | 2021-2025 | |
| Corium, LLC | $353.31 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $192.61 | 2023-2025 | Qelbree, Qelbree |
| Astellas Pharma US INC | $94.00 | 2023 | |
| Lilly USA, LLC | $88.12 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.07 | 2022-2023 | |
| Ironshore Pharmaceuticals INC. | $60.16 | 2024 | |
| Novo Nordisk INC | $53.02 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $33.50 | 2025 | |
| Vanda Pharmaceuticals INC. | $32.74 | 2025 | Fanapt |
| Amgen INC. | $24.51 | 2021 | |
| Exact Sciences Corporation | $21.72 | 2025 | The Cologuard Plus Collection Kit |
| Lundbeck LLC | $21.29 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $20.40 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $19.75 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.51 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.33 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.34 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.